Safety, health & wellbeing
Responsible business plan: Safety, health & wellbeing
We are committed to promoting a safe, healthy and energizing work environment in which our people, and those from third-parties working closely with us, are able to express their talents, drive innovation, and improve business performance.
Details of our 2015 targets in this area are included in our SHE strategy (PDF 119kb) .
2.38 lost time injury/illness cases per million hours worked
7.1 collisions per million km
≥80% of sites or marketing companies offer 3 essential health programmes or services
Maintain or improve the 2011 FOCUS score (69%) for the health & wellbeing question.
Details of our 2015 targets in this area are included in our SHE strategy.View/download our SHE strategy (PDF 119kb)
Number of fatalities.
Combined lost time accident and illness rate (cases per million hours worked).
Collision rate (number per million kilometres driven).
Percentage of sites offering required number of Essential Health programmes or services.
FOCUS score against question: “Senior leaders at AstraZeneca are interested in the well-being of colleagues.”
21% improvement in the lost time injury/illness rate compared to the baseline year (2010). 2012 rate is 2.01.
CPMK is 7.43 - a decrease of 15% on 2011.
91% of our sites around the world offered at least three essential health programmes.
2012 FOCUS score for the Wellbeing question down 3% to 66% (69% in 2011).
During 2012, we undertook a number of activities and initiatives focused on delivery of improvements in key risk areas. These included the launch of a global guide for use in office environments (‘SHE Made Simple’), the introduction of a behavioural SHE initiative aimed at improving safety performance in the global Operations function, and a project to improve the sharing of learning from SHE incidents across the business.
Progress against our 2015 targets for safety, health and wellbeing is summarised below.
- Fatalities (zero tolerance) – We regret that during 2012 two members of the public were killed in two separate road traffic accidents involving AstraZeneca drivers in Russia and Turkey. Detailed investigations into both accidents have been carried out. For the Russian accident, an action plan was formulated to respond to the findings of the investigation and these actions are being tracked. The investigation report for the Turkish accident which happened in October 2012 is not yet finalised. Learning from both accidents will be shared widely across the Group. You can read more about our driver safety improvement programmes in the Driver Safety section.
- Accidents and illnesses – In 2012, the lost time injury/illness rate increased by 3% compared to 2011. However we remain well on track to achieve our 2015 target of a 25% reduction in the lost time injury/illness rate from the 2010 baseline, with an overall 21% reduction achieved so far. An estimated total of 3,778 working days were lost due to workplace accidents and occupational illnesses in 2012 representing a 33% reduction from the previous year.
We continue to work together with our contractors to ensure the same level of safety commitment as we would expect from our own employees. In 2012 the lost time injury rate for contractors working on our global engineering and construction projects and activities was 1.93 per million hours worked, compared to 0.82 in 2011. The rate is significantly lower than the construction industry norms in the countries in which we are working.
The 2012 collisions per million kilometres driven KPI was 7.43 (CPMK), which represents a 15% improvement on 2011 performance. However, we narrowly missed our 2012 target of 7.1 CPMK, but remain close to the glide path for our 2015 target which reflects a 40% reduction from the 2008 baseline.
Health and wellbeing
In 2012 91% of our sites around the world offered at least three essential health programmes for employees, meeting our 2012 target of >= 80%. By 2015 we aim to have >=80% of sites offering all 6 essential health programmes. You can read more about health and wellbeing in AstraZeneca here.
What's next in this section
Diversity & inclusion
Read details of our 2012 performance.Read more